Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2009;119:845-856
Published online before print February 2, 2009, doi: 10.1161/CIRCULATIONAHA.108.816454
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow All Versions of this Article:
119/6/845    most recent
CIRCULATIONAHA.108.816454v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lähteenvuo, J. E.
Right arrow Articles by Ylä-Herttuala, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lähteenvuo, J. E.
Right arrow Articles by Ylä-Herttuala, S.
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Growth factors/cytokines
Right arrow Echocardiography
Right arrow Acute myocardial infarction
Right arrow Gene therapy
Right arrow Endothelium/vascular type/nitric oxide
Right arrowRelated Article

(Circulation. 2009;119:845-856.)
© 2009 American Heart Association, Inc.


Molecular Cardiology

Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms

Johanna E. Lähteenvuo, MD; Markku T. Lähteenvuo, MD; Antti Kivelä, MD; Carolina Rosenlew, MSc; Annelie Falkevall, PhD; Joakim Klar, PhD; Tommi Heikura, MSc; Tuomas T. Rissanen, MD, PhD; Elisa Vähäkangas, MD; Petra Korpisalo, MD; Berndt Enholm, MD, PhD; Peter Carmeliet, MD, PhD; Kari Alitalo, MD, PhD; Ulf Eriksson, PhD; Seppo Ylä-Herttuala, MD, PhD, FESC

From the Department of Biotechnology and Molecular Medicine (J.E.L., M.T.L., A.K., T.H., T.T.R., E.V., P.K., S.Y.-H.), A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland; Ludwig Institute for Cancer Research Ltd, Karolinska Institutet (C.R., A.F., J.K., U.E.), Stockholm, Sweden; Molecular and Cancer Biology Laboratory (B.E., K.A.), Haartman Institute, University of Helsinki, Helsinki, Finland; and Flanders Interuniversity Institute for Biotechnology (P.C.), Katholieke Universiteit Leuven, Leuven, Belgium.

Reprint requests to Seppo Ylä-Herttuala, MD, PhD, FESC, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. E-mail Seppo.Ylaherttuala{at}uku.fi

Received December 5, 2007; accepted December 9, 2008.

Background— New revascularization therapies are urgently needed for patients with severe coronary heart disease who lack conventional treatment options.

Methods and Results— We describe a new proangiogenic approach for these no-option patients using adenoviral (Ad) intramyocardial vascular endothelial growth factor (VEGF)-B186 gene transfer, which induces myocardium-specific angiogenesis and arteriogenesis in pigs and rabbits. After acute infarction, AdVEGF-B186 increased blood vessel area, perfusion, ejection fraction, and collateral artery formation and induced changes toward an ischemia-resistant myocardial phenotype. Soluble VEGF receptor-1 and soluble neuropilin receptor-1 reduced the effects of AdVEGF-B186, whereas neither soluble VEGF receptor-2 nor inhibition of nitric oxide production had this result. The effects of AdVEGF-B186 involved activation of neuropilin receptor-1, which is highly expressed in the myocardium, via recruitment of G-protein-{alpha} interacting protein, terminus C (GIPC) and upregulation of G-protein-{alpha} interacting protein. AdVEGF-B186 also induced an antiapoptotic gene expression profile in cardiomyocytes and had metabolic effects by inducing expression of fatty acid transport protein-4 and lipid and glycogen accumulation in the myocardium.

Conclusions— VEGF-B186 displayed strikingly distinct effects compared with other VEGFs. These effects may be mediated at least in part via a G-protein signaling pathway. Tissue-specificity, high efficiency in ischemic myocardium, and induction of arteriogenesis and antiapoptotic and metabolic effects make AdVEGF-B186 a promising candidate for the treatment of myocardial ischemia.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2009 119: 765-767. [Extract] [Full Text]